Eurobio Scientific Société anonyme (EPA:ALERS)
France · Delayed Price · Currency is EUR 20.80
+0.80 (4.00%)
Aug 3, 2026, 12:54 PM CET
EPA:ALERS Ratios and Metrics
Market cap in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 201 | 245 | 259 | 184 | 231 | 292 | |
Market Cap Growth | -20.99% | -5.26% | 40.97% | -20.51% | -20.91% | 53.73% |
Enterprise Value | 196.71 | 240.52 | 245.49 | 207.19 | 258.98 | 207.4 |
Last Close Price | 20.80 | 24.35 | 25.25 | 16.46 | 20.36 | 26.92 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 42.55 | 51.81 | 64.74 | 38.28 | 9.25 | 4.83 |
Forward PE | 17.70 | 25.50 | 25.38 | 17.33 | 10.63 | 7.73 |
PS Ratio | 1.19 | 1.45 | 1.67 | 2.23 | 0.76 | 1.74 |
PB Ratio | 1.09 | 1.33 | 1.45 | 1.05 | 1.34 | 1.82 |
P/TBV Ratio | - | - | - | - | - | 2.43 |
P/FCF Ratio | 32.05 | 39.02 | 19.24 | 8.08 | 5.74 | 4.56 |
P/OCF Ratio | 10.68 | 13.00 | 15.49 | 6.86 | 5.36 | 4.43 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.17 | 1.43 | 1.59 | 2.52 | 0.85 | 1.24 |
EV/EBITDA Ratio | 7.11 | 8.69 | 8.08 | 7.81 | 6.46 | 2.69 |
EV/EBIT Ratio | 18.31 | 22.39 | 18.41 | 16.89 | 8.39 | 2.96 |
EV/FCF Ratio | 31.31 | 38.28 | 18.26 | 9.12 | 6.44 | 3.24 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.09 | 0.09 | 0.05 | 0.56 | 0.57 | 0.08 |
Debt / EBITDA Ratio | 0.58 | 0.58 | 0.32 | 4.25 | 2.84 | 0.23 |
Debt / FCF Ratio | 2.55 | 2.55 | 0.73 | 4.96 | 2.83 | 0.28 |
Net Debt / Equity Ratio | -0.02 | -0.02 | -0.07 | 0.14 | 0.16 | -0.53 |
Net Debt / EBITDA Ratio | -0.17 | -0.17 | -0.44 | 0.89 | 0.70 | -1.10 |
Net Debt / FCF Ratio | -0.74 | -0.74 | -0.99 | 1.04 | 0.70 | -1.32 |
Asset Turnover | 0.66 | 0.66 | 0.54 | 0.25 | 1.13 | 0.88 |
Inventory Turnover | 3.30 | 3.30 | 3.43 | 2.23 | 4.30 | 4.88 |
Quick Ratio | 0.86 | 0.86 | 0.81 | 2.19 | 2.07 | 4.05 |
Current Ratio | 1.30 | 1.30 | 1.19 | 2.72 | 2.59 | 4.81 |
Return on Equity (ROE) | 2.68% | 2.68% | 2.26% | 4.68% | 14.97% | 46.59% |
Return on Assets (ROA) | 5.75% | 5.75% | 6.34% | 3.47% | 13.25% | 32.60% |
Return on Invested Capital (ROIC) | 8.25% | 8.58% | 9.99% | 5.62% | 25.89% | 84.64% |
Return on Capital Employed (ROCE) | 5.83% | 5.83% | 5.99% | 4.57% | 13.81% | 46.99% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.42% | 1.93% | 1.54% | 2.61% | 10.81% | 20.69% |
FCF Yield | 3.12% | 2.56% | 5.20% | 12.37% | 17.42% | 21.94% |
Buyback Yield / Dilution | - | 0.00% | 8.63% | 1.40% | -4.59% | 3.35% |
Total Shareholder Return | - | 0.00% | 8.63% | 1.40% | -4.59% | 3.35% |